Superluminal Medicines
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
15 Necco St Fl 4, Boston, Massachusetts,...Phone Number
(781) 786-8484Website
www.superluminalrx.comRevenue
$10.6 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
1
1
About Superluminal Medicines
Superluminal Medicines is a biotechnology company pioneering AI-driven drug discovery by combining machine learning, structural biology, protein dynamics and medicinal chemistry. Its platform focuses on challenging GPCR targets and aims to develop selective small-molecule therapies for obesity, cardiometabolic diseases and other areas of high unmet medical need.Explore more
Superluminal Medicines Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Superluminal Medicines your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Superluminal Medicines, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Superluminal Medicines launches new products
Funding: Get notified immidiatlly once Superluminal Medicines has new funding data
Click to see if Superluminal Medicines had a recent Job posting/layoffs
Earning: See what the market has to say on Superluminal Medicines recently announced quarterly report
Check if Superluminal Medicines has recently received funding, and reach out quickly before it becomes old news!
Check out if Superluminal Medicines is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Superluminal Medicines
Recommended Actions
Reach out to Masked Content who joined Superluminal Medicines as Masked Content
Find 2 more new buyers
Compare Similar Companies to Superluminal Medicines
Compare insights from companies similar to Superluminal Medicines, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Superluminal Medicines is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Superluminal Medicines is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Superluminal Medicines.
Superluminal Medicines financials insights
Gather financial insights about Superluminal Medicines, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Angel/Seed
$33M
2024
Series A
$120M
2025
Debt
$5M
2026
Series B
$60M
Superluminal Medicines Tech Stack
A closer look at the technologies used by Superluminal Medicines
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Superluminal Medicines News & Media
Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity
Collaboration focused on undisclosed GPCR targets Company to receive an upfront and near-term payments, including an equity investment, as well as additional development and commercial milestones, and tiered royalties BOSTON, Aug. 14, 2025 /PRNewswire/ -- Superluminal Medicines, a drug...Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship
FUJISAWA, Japan & BOSTON--(BUSINESS WIRE)--Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate on drug discovery targeting specific molecular mechanisms associated with challenging biological targets. The two companies have built a strong relationship through prior collaborations. Axcelead DDP provided high-quality in vivo pharmacological evaluations of proprietary compounds developed by Superluminal usingSuperluminal Medicines Nets $120M Series A
BOSTON, MA, Superluminal Medicines announced the closing of a $120 million Series A funding round led by RA Capital.Superluminal Medicines Announces Formation of Scientific Advisory Board
Superluminal Medicines, Inc. announced the formation of its Scientific Advisory Board (SAB).
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Superluminal Medicines
Sign Up For FreeTo access detailed company insights
Superluminal Medicines is a biotechnology company pioneering AI-driven drug discovery by combining machine learning, structural biology, protein dynamics and medicinal chemistry. Its platform focuses on challenging GPCR targets and aims to develop selective small-molecule therapies for obesity, cardiometabolic diseases and other areas of high unmet... Read More
